Resolving lesions in human cutaneous leishmaniasis predominantly harbour chemokine receptor CXCR3-positive T helper 1/T cytotoxic type 1 cells

British Journal of Dermatology

Volumn 162, Issue 4, 2010, Pages 870-874

  Geiger, B ^a   Wenzel, J ^b   Hantschke, M ^c   Haase, I ^d   Stander S ^e   Von Stebut, E ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b UNIVERSITY OF BONN   (Germany)

^c Dermatopathologische Gemeinschaftspraxis   (Germany)

^d UNIVERSITY OF COLOGNE   (Germany)

^e UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Human; Leishmaniasis; Th1 Th2 cells

Indexed keywords

CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CXCR3; GAMMA INTERFERON; CHEMOKINE RECEPTOR; CXCR3 PROTEIN, HUMAN; CXCR3 PROTEIN, MOUSE;

ADULT; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DISEASE DURATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LANGERHANS CELL; LYMPHOCYTE COUNT; MACROPHAGE; MALE; PRIORITY JOURNAL; SKIN BIOPSY; SKIN LEISHMANIASIS; TH1 CELL; TH2 CELL; ANIMAL; CELL CULTURE; CYTOLOGY; IMMUNOLOGY; MOUSE; PATHOLOGY;

ADULT; ANIMALS; CELLS, CULTURED; FEMALE; HUMANS; LEISHMANIASIS, CUTANEOUS; MALE; MICE; RECEPTORS, CHEMOKINE; RECEPTORS, CXCR3; T-LYMPHOCYTES, CYTOTOXIC; TH1 CELLS;

EID: 77949869444     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2009.09573.x     Document Type: Article

References (13)

1. World Health Organisation. WHO Report on global surveillance of epidemic-prone infectious diseases - Leishmaniasis, 2000. Available at: http://www.cdc.gov/cogh/gdd/pdf/WHO-Report-on-Global-Surveillance-of-Epidemic- Prone-Infectious-Diseases.pdf (last accessed 11 November 2009).
2. Palumbo E. Current treatment for cutaneous leishmaniasis: a review. Am J Ther 2009 16 : 178 182.
3. Sacks D, Noben-Trauth N. The immunology of susceptibility and resistance to Leishmania major in mice. Nat Rev Immunol 2002 2 : 845 858.
4. von Stebut E. Cutaneous Leishmania infection: progress in pathogenesis research and experimental therapy. Exp Dermatol 2007 16 : 340 346.
5. Bottrel RL, Dutra WO, Martins FA et al. Flow cytometric determination of cellular sources and frequencies of key cytokine-producing lymphocytes directed against recombinant LACK and soluble Leishmania antigen in human cutaneous leishmaniasis. Infect Immun 2001 69 : 3232 3239.
6. Bourreau E, Gardon J, Pradinaud R et al. Th2 responses predominate during the early phases of infection in patients with localized cutaneous leishmaniasis and precede the development of Th1 responses. Infect Immun 2003 71 : 2244 2246.
7. Rogers KA, DeKrey GK, Mbow ML et al. Type 1 and type 2 responses to Leishmania major. FEMS Microbiol Lett 2002 209 : 1 7.
8. Kolde G, Luger T, Sorg C et al. Successful treatment of cutaneous leishmaniasis using systemic interferon-gamma. Dermatology 1996 192 : 56 60.
9. Wakugawa M, Nakamura K, Kakinuma T et al. CC chemokine receptor 4 expression on peripheral blood CD4+ T cells reflects disease activity of atopic dermatitis. J Invest Dermatol 2001 117 : 188 196.
10. Koch MA, Tucker-Heard G, Perdue NR et al. The transcription factor T-bet controls regulatory T cell homeostasis and function during type 1 inflammation. Nat Immunol 2009 10 : 595 602.
11. Moll H, Fuchs H, Blank C et al. Langerhans cells transport Leishmania major from the infected skin to the draining lymph node for presentation to antigen-specific T cells. Eur J Immunol 1993 23 : 1595 1601.
12. Rosas LE, Barbi J, Lu B et al. CXCR3-/- mice mount an efficient Th1 response but fail to control Leishmania major infection. Eur J Immunol 2005 35 : 515 523.
13. Barbi J, Brombacher F, Satoskar AR. T cells from Leishmania major-susceptible BALB/c mice have a defect in efficiently up-regulating CXCR3 upon activation. J Immunol 2008 181 : 4613 4620.